Author:
Souayah Nizar,Michas-Martin P.A.,Nasar Abu,Krivitskaya Nataliya,Yacoub Hussam A.,Khan Hafiz,Qureshi Adnan I.
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference27 articles.
1. Product approval information-licensing action. GARDASIL® questions and answers. http://www.asccp.org/pdfs/hpv/FDAFactSheet.pdf [accessed 01.03.10].
2. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions;N Engl J Med,2007
3. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial;Paavonen;Lancet,2007
4. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials;Joura;Lancet,2007
5. An analysis by the National Vaccine Information Center of Gardasil & Menactra adverse event reports to the Vaccine Adverse Events Reporting System (VAERS),2009
Cited by
63 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献